This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): rosuvastatin calcium
Description: The active ingredient of Crestor, Rosuvastatin calcium, inhibits HMG-CoA reductase, an enzyme required for the synthesis of cholesterol. Crestor has been shown to reduce total cholesterol, low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apo B) in patients.
Deal Structure: AstraZeneca licensed worldwide rights to Crestor from Shionogi in 1998.
On May 16, 2002, the two companies announced an agreement to co-market Crestor in Japan. AstraZeneca will be the manufacturer and AstraZeneca and Shionogi will market the product under one brand, using their respective distribution channels.
In August 2008, Abbott and AstraZeneca announced that they entered into an agreement for Abbott to promote Crestor. Under the terms of the agreement, Abbott will obtain the non-exclusive right to promote Crestor alongside AstraZeneca in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.
In November 2009, Simcere announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical. The acquisition of the manufacturing license will be effected through the acquisition of equity in Tianda as well as transfer of certain technologies from Tianda. Upon completion of the acquisition,...See full deal structure in Biomedtracker
Partners: Shionogi & Co. Ltd. AbbVie Inc. Simcere Pharmaceutical Group
Pink Sheet Crestor FDA Reviewers
Pink Sheet Crestor Clinical Development
Additional information available to subscribers only: